FILE:ESRX/ESRX-8K-20120810105852.txt.gz
EVENTS:	Regulation FD Disclosure
TEXT:
ITEM: Regulation FD Disclosure
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (General Instruction A.2. below):
see
 
 
 
 
 
 
 
Item 7.01 Regulation FD Disclosure
Earlier this week, Express Scripts Holding Company (the "Company") disclosed that it was assessing strategic options for many of the businesses included in its Other Business Operations segment for ultimate disposition. In communications with its employees, the Company has provided additional details regarding which businesses may be divested. Specifically, the Company indicated that it currently intends to pursue divestiture of the diabetic testing supply and related businesses under its Liberty brand, as well as certain business units operated under the Company's United BioSource Corporation (or UBC) subsidiary. The Company also announced its decision to dissolve the Company's joint venture in China, wind down its business in Germany and France, and exit its European headquarters in Amsterdam.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 


